Sawai Pharmaceutical Completes Acquisition Of Upsher-Smith Laboratories
Sawai Pharmaceutical Co., Ltd., (Sawai) and Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that Sawai, a leading Japanese generic pharmaceuticals manufacturer, has successfully completed its acquisition of Upsher-Smith's generics business. Sawai intends to retain operations in Minnesota and Colorado.
As previously announced, the acquisition provides Sawai with an opportunity for growth in the U.S. market where Upsher-Smith has an established, extensive portfolio of quality, high-value generic products. Rusty Field, the current President of Upsher-Smith, will take on the additional role of CEO.
"This is a momentous day for both Sawai and Upsher-Smith," said Mitsuo Sawai, President, Sawai Pharmaceutical Company. "The acquisition of Upsher-Smith adds significantly to our capabilities and supports the acceleration of our vision of becoming a globally recognized generic drug company. Upsher-Smith's manufacturing and commercial strength, strong distribution network and established relationships combined with Sawai's research and development capabilities and state-of-the-art manufacturing technology provide the opportunity to further enhance our ability to bring high-quality, high-value generic pharmaceutical products to patients both in Japan and the United States."
Rusty Field, President and CEO, Upsher-Smith added, "This acquisition brings together two closely-aligned companies with similar values. Sawai is one of the largest generic pharmaceutical companies in Japan and Upsher-Smith has an established portfolio of generic products in the United States. This deal represents an energizing growth opportunity for the generics business both in the U.S. and abroad."
Sawai's financial advisors are Torreya Partners LLC and SMBC Nikko Securities Inc., and legal counsel is Debevoise & Plimpton LLP. J.P. Morgan Securities LLC and BMO Capital Markets served as financial advisors to Upsher-Smith on this transaction and Lindquist & Vennum LLP served as the Company's legal counsel.
Looking for chemical products? Let suppliers reach out to you!
2026-07-14
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The project of fine chemicals with 4000 t/a Tebuconazole and Diflufenican is to be built
-
P&G launched the first major group acquisition in 2023
-
Rainbow acquires S.A. to accelerate market expansion in the EU
-
China丨Grand Holding acquired Microbe with ¥ 830 million to lay out for biopesticide industry chain
-
China丨Maxunitech acquired Shijie, became the tops in Sulfentrazone, Flumioxazin technical production capacity
-
China丨Flagchem acquired 100% equity of Suke to improve its formulation capacity
-
Pharmaconex 2022
-
CPHI Korea 2022
-
Shandong Pharmaceutical Companies Grab Over $1 Billion of Antithrombotic Drugs for The First Imitation, Original Research Drugs Soared 5527%
-
ECHEMI International Trade Business School Bangladesh Pharmaceutical Summary
Recommend Reading
-
Supporting Each Other | ECHEMI Employees Voluntarily Raise Funds for Flood Relief in Southern Thailand
-
Notice of 2026 Chinese New Year Holiday
-
International Workers' Day Holiday Notice and Service Arrangement
-
China’s API Export Shift Takes Center Stage at API China 2026
-
Address Change Declaration(ECHEMI SPECIALTIES)
-
HighChem and Jiangxi Zhongxin Aksum Launch HFO-1233zd in Japan Low GWP and Zero ODP Products Target Surging Insulation and Semiconductor Demand
-
1 Million Ton Green Methanol Project Signed in Fujian with 15 Billion Yuan Investment Global Partners Set Sights on Clean Energy Chain
-
DuPont Q2 Net Sales Hit $3.3 Billion with 35 Percent Profit Jump Electronics Division Set for $9 Billion Value Boost
-
Equipment Change & Clustered Maintenance TDI Price Increase Exceeds 35%
-
SABIC Q2 Net Income Surges to SAR 500 Million on 3 Percent Sales Rise Board Approves SAR 4.5 Billion Dividend